Effect of multidrug therapy on the prognosis of Mycobacterium avium complex pulmonary disease.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
23 Feb 2024
23 Feb 2024
Historique:
received:
04
10
2023
accepted:
20
02
2024
medline:
24
2
2024
pubmed:
24
2
2024
entrez:
23
2
2024
Statut:
epublish
Résumé
Multidrug therapy for Mycobacterium avium complex pulmonary disease (MAC-PD) results in negative sputum cultures. However, the prognostic value of this treatment approach remains unclear. This study aimed to clarify whether multidrug therapy reduces the incidence of events related to MAC-PD and improves the mortality rate. Patients who met the diagnostic criteria for MAC-PD at our hospital between 2003 and 2019 were retrospectively evaluated using medical records. Events related to MAC-PD were defined as hospitalisation for haemoptysis or respiratory infection and the development of chronic respiratory failure. There were 90 and 108 patients in the multidrug and observation groups, respectively. The median observation period was 86 months. Intergroup differences in body mass index, proportion of patients with cavities, and erythrocyte sedimentation rate were not significant. However, the observation group was older with a higher mean age (multidrug group: 62 years, observation group: 69 years; P < 0.001) and had a higher proportion of male patients (multidrug group: 13/90 [14.4%], observation group: 35/108 [32.4%]; P < 0.01). Furthermore, intergroup differences in the incidence of events related to MAC-PD (multidrug group: 26.69/1000 person-years, observation group: 25.49/1000 person-years), MAC-PD-associated mortality rate (multidrug group: 12.13/1000 person-years, observation group: 12.74/1000 person-years), and total mortality (multidrug group: 24.26/1000 person-years, observation group: 29.50/1000 person-years) were not significant. Many patients relapse even after multidrug therapy, and our findings suggest that multidrug therapy has no effect in preventing the onset of respiratory events or prolonging life expectancy.
Identifiants
pubmed: 38396118
doi: 10.1038/s41598-024-55135-0
pii: 10.1038/s41598-024-55135-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4438Informations de copyright
© 2024. The Author(s).
Références
Thomson, R. M., NTM Working Group at Queensland TB Control Centre and Queensland Mycobacterial Reference Laboratory. Changing epidemiology of pulmonary nontuberculous mycobacteria infections. Emerg. Infect. Dis. 16, 1576–1583. https://doi.org/10.3201/eid1610.091201 (2010).
doi: 10.3201/eid1610.091201
pubmed: 20875283
pmcid: 3294381
Henkle, E., Hedberg, K., Schafer, S., Novosad, S. & Winthrop, K. L. Population-based incidence of pulmonary non-tuberculous mycobacterial disease in Oregon 2007 to 2012. Ann. Am. Thorac. Soc. 12, 642–647. https://doi.org/10.1513/AnnalsATS.201412-559OC (2015).
doi: 10.1513/AnnalsATS.201412-559OC
pubmed: 25692495
pmcid: 4418336
Namkoong, H. et al. Epidemiology of pulmonary non-tuberculous mycobacterial disease, Japan. Emerg. Infect. Dis. 22, 1116–1117. https://doi.org/10.3201/eid2206.151086 (2016).
doi: 10.3201/eid2206.151086
pubmed: 27191735
pmcid: 4880076
Forbes, B. A. Mycobacterial taxonomy. J. Clin. Microbiol. 55, 380–383. https://doi.org/10.1128/JCM.01287-16 (2017).
doi: 10.1128/JCM.01287-16
pubmed: 27927928
pmcid: 5277506
Marras, T. K. & Daley, C. L. Epidemiology of human pulmonary infection with non-tuberculous mycobacteria. Clin. Chest Med. 23, 553–567. https://doi.org/10.1016/S0272-5231(02)00019-9 (2002).
doi: 10.1016/S0272-5231(02)00019-9
pubmed: 12370992
Simons, S. et al. Non-tuberculous mycobacteria in respiratory tract infections, eastern Asia. Emerg. Infect. Dis. 17, 343–349. https://doi.org/10.3201/eid1703.100604 (2011).
doi: 10.3201/eid1703.100604
pubmed: 21392422
pmcid: 3165997
Hayashi, M. et al. Prognostic factors of 634 HIV-negative patients with Mycobacterium avium complex lung disease. Am. J. Respir. Crit. Care Med. 185, 575–583. https://doi.org/10.1164/rccm.201107-1203OC (2012).
doi: 10.1164/rccm.201107-1203OC
pubmed: 22199005
Pasipanodya, J. G., Ogbonna, D., Deshpande, D., Srivastava, S. & Gumbo, T. Meta-analyses and the evidence base for microbial outcomes in the treatment of pulmonary Mycobacterium avium-intracellulare complex disease. J. Antimicrob. Chemother. 72(Suppl 2), i3–i19. https://doi.org/10.1093/jac/dkx311 (2017).
doi: 10.1093/jac/dkx311
pubmed: 28922813
Kadota, J. I., Kurashima, A. & Suzuki, K. The clinical efficacy of a clarithromycin-based regimen for Mycobacterium avium complex disease: A nationwide post-marketing study. J. Infect. Chemother. 23, 293–300. https://doi.org/10.1016/j.jiac.2017.01.007 (2017).
doi: 10.1016/j.jiac.2017.01.007
pubmed: 28254517
Daley, C. L. et al. Treatment of non-tuberculous mycobacterial pulmonary disease: An official ATS/ERS/ESCMID/IDSA clinical practice guideline. Clin. Infect. Dis. 71, e1–e36. https://doi.org/10.1093/cid/ciaa241 (2020).
doi: 10.1093/cid/ciaa241
pubmed: 32628747
pmcid: 7768748
Kim, H. J. et al. BACES score for predicting mortality in non-tuberculous mycobacterial pulmonary disease. Am. J. Respir. Crit. Care Med. 203, 230–236. https://doi.org/10.1164/rccm.202004-1418OC (2021).
doi: 10.1164/rccm.202004-1418OC
pubmed: 32721164
Kim, H. J. et al. Usefulness of the BACES score in non-tuberculous mycobacterial pulmonary disease for various clinical outcomes. Sci. Rep. 13, 7495. https://doi.org/10.1038/s41598-023-33782-z (2023).
doi: 10.1038/s41598-023-33782-z
pubmed: 37160912
pmcid: 10170159
Kanda, Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 48, 452–458. https://doi.org/10.1038/bmt.2012.244 (2013).
doi: 10.1038/bmt.2012.244
pubmed: 23208313
Jhun, B. W. et al. Prognostic factors associated with long-term mortality in 1445 patients with non-tuberculous mycobacterial pulmonary disease: A 15-year follow-up study. Eur. Respir. J. 55, 1900798. https://doi.org/10.1183/13993003.00798-2019 (2020).
doi: 10.1183/13993003.00798-2019
pubmed: 31619468
Bemer, P. et al. Management of patients with pulmonary mycobacteriosis in France: A multicenter retrospective cohort study. BMC Pulm. Med. 21, 333. https://doi.org/10.1186/s12890-021-01701-5 (2021).
doi: 10.1186/s12890-021-01701-5
pubmed: 34702233
pmcid: 8549171
Im, Y. et al. Impact of time between diagnosis and treatment for non-tuberculous mycobacterial pulmonary disease on culture conversion and all-cause mortality. Chest 161, 1192–1200. https://doi.org/10.1016/j.chest.2021.10.048 (2022).
doi: 10.1016/j.chest.2021.10.048
pubmed: 34793759
Yan, M., Brode, S. K. & Marras, T. K. The other non-tuberculous mycobacteria: Clinical aspects of lung disease caused by less common slowly growing non-tuberculous mycobacteria species. Chest 163, 281–291. https://doi.org/10.1016/j.chest.2022.09.025 (2023).
doi: 10.1016/j.chest.2022.09.025
pubmed: 36174743
Broncano-Lavado, A., Senhaji-Kacha, A., Santamaría-Corral, G., Esteban, J. & García-Quintanilla, M. Alternatives to antibiotics against Mycobacterium abscessus. Antibiotics (Basel) 11, 1322. https://doi.org/10.3390/antibiotics11101322 (2022).
doi: 10.3390/antibiotics11101322
pubmed: 36289979
Pan, S. W. et al. Impact of different subspecies on disease progression in initially untreated patients with Mycobacterium avium complex lung disease. Clin. Microbiol. Infect. 27(467), e9-467.e14. https://doi.org/10.1016/j.cmi.2020.04.020 (2021).
doi: 10.1016/j.cmi.2020.04.020
Kim, J. Y. et al. Impact of treatment on long-term survival of patients with Mycobacterium avium complex pulmonary disease. Clin. Infect. Dis. 77, 120–126. https://doi.org/10.1093/cid/ciad108 (2023).
doi: 10.1093/cid/ciad108
pubmed: 36861203
Theuretzbacher, U. et al. In memoriam: William A. Craig. Antimicrob. Agents Chemother. 59, 2971. https://doi.org/10.1128/AAC.00849-15 (2015).
doi: 10.1128/AAC.00849-15
pubmed: 25896702
pmcid: 4432111
Koh, W. J. et al. Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype. Eur. Respir. J. 50, 1602503. https://doi.org/10.1183/13993003.02503-2016 (2017).
doi: 10.1183/13993003.02503-2016
pubmed: 28954780
Czaja, C. A. et al. Improvement in quality of life after therapy for Mycobacterium abscessus group lung infection. A prospective cohort study. Ann. Am. Thorac. Soc. 13, 40–48. https://doi.org/10.1513/AnnalsATS.201508-529OC (2016).
doi: 10.1513/AnnalsATS.201508-529OC
pubmed: 26540302
Henkle, E. et al. Patient-centered research priorities for pulmonary non-tuberculous mycobacteria (NTM) infection. An NTM research consortium workshop report. Ann. Am. Thorac. Soc 13, S379–S384. https://doi.org/10.1513/AnnalsATS.201605-387WS (2016).
doi: 10.1513/AnnalsATS.201605-387WS
pubmed: 27627485
pmcid: 5461946
Hama, M. et al. Health-related quality of life in patients with pulmonary non-tuberculous mycobacteria infection. Int. J. Tuberc. Lung Dis. 20, 747–752. https://doi.org/10.5588/ijtld.15.0460 (2016).
doi: 10.5588/ijtld.15.0460
pubmed: 27155176